FIELD: medicine.
SUBSTANCE: invention represents product in form of solid dispersion, containing N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea or its pharmaceutically acceptable salt, at least, one pharmaceutically acceptable water-soluble polymer carrier and, at least, one pharmaceutically acceptable surface-active substance.
EFFECT: solid dispersion is suitable for peroral introduction to requiring it subject for cancer treatment.
24 cl, 4 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| THIENO[3,2-c]PYRIDINE DERIVATIVES AS KINASE INHIBITORS FOR USE IN CANCER TREATMENT | 2009 |
|
RU2480472C2 |
| PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS TAM AND MET KINASE INHIBITORS | 2019 |
|
RU2773611C1 |
| HETEROCYCLIC ANALOGUES OF PYRIMIDINES AS JAK INHIBITORS | 2012 |
|
RU2564419C1 |
| NOVEL CONDENSED PYRIDINE DERIVATIVES USED AS C-MET TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619130C2 |
| PHARMACEUTICAL COMPOSITION FOR USING IN THERAPY OF MALIGNANT NEOPLASM COMPRISING COMBINATION OF BISPHOSPHONATE, COX-2 INHIBITOR AND TAXOL | 2002 |
|
RU2317819C2 |
| NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | 2013 |
|
RU2660429C2 |
| HETEROARYL COMPOUNDS AS IRAK TYPE II INHIBITORS AND THEIR USE | 2019 |
|
RU2810338C2 |
| SERINE/THREONINE KINASE INHIBITORS | 2013 |
|
RU2650501C2 |
| METHOD FOR APPLYING CYCLOOXYGENASE-2 INHIBITOR FOR TREATMENT AND PROPHYLAXIS OF NEOPLASIA | 1997 |
|
RU2239429C2 |
| JAK-INHIBITING TRIAZOLOPYRIDINE COMPOUNDS AND METHODS | 2009 |
|
RU2560153C2 |
